Canorof 25 mg Injection
PDF Leaflet Revision Date: 27 September 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Initial therapy for inflammatory and degenerative rheumatic diseases and mild to moderate pain.
Dosage (summary)
75 mg IM once daily, may increase to twice daily in severe cases; max 150 mg/day.
Onset of Action / Duration
Onset: 10-20 mins, Duration: 24 hours
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in late pregnancy; avoid during breastfeeding.
Key Drug Interactions
- Lithium
- Digoxin
- Anticoagulants
- Corticosteroids
- SSRIs
Contraindications
- Hypersensitivity to diclofenac
- Active gastrointestinal ulcers
- History of gastrointestinal bleeding
- Severe renal impairment
- Pregnancy after 20 weeks
- Lactation
Common side effects
- Gastrointestinal discomfort
- Headache
- Dizziness
- Skin rash
- Hypertension
Counselling Points
- Use the lowest effective dose
- Monitor for gastrointestinal symptoms
- Avoid in late pregnancy
- Report any skin reactions immediately
Serious warnings
- Risk of gastrointestinal bleeding
- Serious skin reactions
- DRESS syndrome
- Renal and hepatic effects
Important Disclaimer
The Canorof 25 mg Injection professional information leaflet below is the property of Austell Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
